After eleven years of review and five national conferences, Health Canada is following the lead of Malta in regulating consumer protection of drug ingredients. “Canada is not particularly good at this,” said Dr. Sholom Glouberman, president of the Patients’ Association of Canada.
This content is for Blacklock’s Reporter members only. Please login to view this content. (Register here.)
